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Compound MMH02 Possesses Toxicity Against Human Cancer Cells With Sparing
of Normal MonocytesFor cancer treatment with cytotoxic agents, the major dose-
limiting factor is their toxicity to normal cells and tissues. This
safety consideration is particularly critical in the elderly cancer
patients, as they are known as a less-tolerant population.1
Leukemia is the most common hematological malignancy with
high risk of relapse after treatment.2 Pancreatic cancer remains
a disease with unfavorable clinical features, including difﬁculty in
early diagnosis, rapid progression, and resistance to chemotherapy
and radiotherapy.3 Similar poor clinical outcome is noted in esoph-
ageal cancer, hepatoma, and locally advanced cervical cancer.4
Clearly, development of novel agents against these devastating
malignancies with less toxicity is urgently needed in clinical
practice.
In this study, we isolated a novel compound from fruiting body
of Antrodia cinnamomea, namely, Lanosta-8,24-dien-3b,15a,21-triol
(chemical formula: C30H50O3; molecular weight, 458) (Fig. 1). We
thereby designated this novel compound as MMH02 and reported
that MMH02 could inhibit the viability of selective types of cancer
cells but not normal monocytes.
As for results, MMH02 markedly inhibited the growth of
human leukemia U937, pancreatic BxPc-3, esophageal 81T, hepa-
toma HA22T/VGH, and cervical HeLa cancer cells, but not ovarian
adenocarcinoma SKOV-3 cells, by using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay.5 The
growth inhibitory rates for these cancer cells ranged from
48.5% to 99.8%. In leukemic U937 cells, it resulted in a unique
pattern of cell cycle distribution, including hypoploidy, G2/M
arrest, and polyploidy (Fig. 2). The modes of cell death in U937
cells include apoptosis and mitotic catastrophe. For apoptosis,
MMH02 induced oligonucleosomal fragmentation of genomic
DNA, a hallmark of apoptosis, noted by DNA electrophoresisFig. 1. The chemical structure of MMH02.
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doi:10.1016/j.ijge.2010.12.001(Fig. 3). Estimation of apoptotic amount by the hypoploid
population demonstrated in DNA histogram shows an apoptotic
percentage up to 51.3%. MMH02 did not reduce the mitochon-
drial transmembrane potential, indicating a mitochondria-
independent pathway. Caspase 3 and pan-caspase inhibitors
could block the camptothecin-induced growth inhibition but
not that induced by MMH02. Moreover, the expression of caspase
3 and 8 was not altered by MMH02. Taken together, MMH02 may
induce apoptosis in a caspase-independent pathway. MMH02
might also induce mitotic catastrophe, another mode of cell
death, according to the development of both distinct morpholog-
ical feature and polyploidy cells. Cell proliferation assessed by
clonogenicity was also inhibited in U937 cells. In pancreaticFig. 2. Cell cycle analysis of human leukemic U937 cells treated by MMH02. Represen-
tative DNA histograms are demonstrated. (A) Control and (B) MMH02 (2.5 mg/mL for
2 days).
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Fig. 3. DNA gel electrophoresis. Lane 1, molecular maker; lane 2, control; lane 3,
MMH02 (5 mg/mL for 24 h).
Letter to the Editor208cancer BxPc-3 cells, MMH02 induced extensive apoptosis with up
to 57.1% 3.5% hypoploid population noted. Intriguingly, only
slight viability inhibition by MMH02 (less than 10%) was notedin human normal monocytes isolated from peripheral blood
mononuclear cells, the normal counterpart of myeloid leukemic
cells.
In conclusion, MMH02 possesses preferential cytotoxicity
against human leukemia, pancreatic cancer, esophageal cancer,
hepatoma, and cervical cancer cells without toxicity to normal
monocytes. The in vivo experiment for validation of in vitro results
and examination of normal organ toxicity is underway.
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